Diamond–Blackfan anemia

Last updated • 5 min readFrom Wikipedia, The Free Encyclopedia
Diamond–Blackfan anemia
Other namesBlackfan-Diamond anemia, inherited pure red cell aplasia, [1] inherited erythroblastopenia [2]
Specialty Hematology

Diamond–Blackfan anemia (DBA) is a congenital erythroid aplasia that usually presents in infancy. [3] DBA causes low red blood cell counts (anemia), without substantially affecting the other blood components (the platelets and the white blood cells), which are usually normal. This is in contrast to Shwachman–Bodian–Diamond syndrome, in which the bone marrow defect results primarily in neutropenia, and Fanconi anemia, where all cell lines are affected resulting in pancytopenia. There is a risk to develop acute myelogenous leukemia (AML) and certain other cancers. [4]

Contents

A variety of other congenital abnormalities may also occur in DBA, such as hand anomalies.

Signs and symptoms

Diamond–Blackfan anemia is characterized by normocytic or macrocytic anemia (low red blood cell counts) with decreased erythroid progenitor cells in the bone marrow. This usually develops during the neonatal period. About 47% of affected individuals also have a variety of congenital abnormalities, including craniofacial malformations, thumb or upper limb abnormalities, cardiac defects, urogenital malformations, and cleft palate. [5] Low birth weight and generalized growth delay are sometimes observed. DBA patients have a modest risk of developing leukemia and other malignancies. [6]

Genetics

Most pedigrees suggest an autosomal dominant mode of inheritance [1] with incomplete penetrance. [7] Approximately 10–25% of DBA occurs with a family history of disease.

~70% of DBA cases can be attributed genetic mutations affecting ribosomal protein genes. [8] The disease is characterized by genetic heterogeneity, affecting different ribosomal gene loci: [9] Exceptions to this paradigm have been demonstrated, such as with rare mutations of transcription factor GATA1. [10] [11] RPS19, RPL5, RPS26, and RPL11 are the most frequently mutated genes in DBA patients. [8] Given that ribosome function is essential for life, DBA patients carry loss-of-function alleles affecting only one copy. Initial descriptions of DBA patients primarily concentrated on nonsense and missense mutations within ribosomal protein coding sequences. However, recent findings suggest that extended splice site variations have not been sufficiently recognized and are quite common. [8] Recent studies have begun to characterize the molecular signatures associated with specific mutations that lead to aberrant splicing impacting ribosomal proteins such as RPL11. [12]

DBA types
namechromosomegenotype [9] phenotype proteindisruption(cite)(cite)
DBA1 [9] 19q13.2 603474 105650 RPS19 30S to 18S [13] : 291 (cite)
DBA28p23-p22unknown 606129
DBA310q22-q23 602412 610629 RPS24 [14] 30S to 18S [13] : 291 (cite)
DBA415q 180472 612527 RPS17 [15] 30S to 18S [13] : 291 
DBA53q29-qter 180468 612528 RPL35A [16] 32S to 5.8S/28S [13] : 291 (cite)
DBA61p22.1 603634 612561 RPL5 [17] 32S to 5.8S/28S [13] : 291 
DBA71p36.1-p35 604175 612562 RPL11 [17] 32S to 5.8S/28S [13] : 291 
DBA82p25 603658 612563 RPS7 [17] 30S to 18S [13] : 291 
DBA96p 603632 613308 RPS10 [9] 30S to 18S [18]
DBA1012q 603701 613309 RPS26 30S to 18S [19]
DBA1117p13 603704 614900 RPL26 30S to 18S [19]
DBA123p24 604174 615550 RPL15 45S to 32S [20]
DBA1314q 603633 615909 RPS29
"other" TSR2, [21] RPS28, [21] GATA1

SLC49A1 (FLVCR1)

In 1997, a patient was identified who carried a rare balanced chromosomal translocation involving chromosome 19 and the X chromosome. This suggested that the affected gene might lie in one of the two regions that were disrupted by this cytogenetic anomaly. Linkage analysis in affected families also implicated this region in disease, and led to the cloning of the first DBA gene. About 20–25% of DBA cases are caused by mutations in the ribosome protein S19 (RPS19) gene on chromosome 19 at cytogenetic position 19q13.2. Some previously undiagnosed relatives of DBA patients were found to carry mutations, and also had increased adenosine deaminase levels in their red blood cells, but had no other overt signs of disease.[ citation needed ]

A subsequent study of families with no evidence of RPS19 mutations determined that 18 of 38 families showed evidence for involvement of an unknown gene on chromosome 8 at 8p23.3-8p22. [22] The precise genetic defect in these families has not yet been delineated.

Malformations are seen more frequently with DBA6 RPL5 and DBA7 RPL11 mutations. [7]

The genetic abnormalities underpinning the combination of DBA with Treacher Collins syndrome (TCS)/mandibulofacial dysostosis (MFD) phenotypes are heterogeneous, including RPS26 (the known DBA10 gene), TSR2 which encodes a direct binding partner of RPS26, and RPS28 . [21]

Molecular basis

The phenotype of DBA patients suggests a hematological stem cell defect specifically affecting the erythroid progenitor population. Loss of ribosomal function might be predicted to affect translation and protein biosynthesis broadly and impact many tissues. However, DBA is characterized by dominant inheritance, and arises from partial loss of ribosomal function, so it is possible that erythroid progenitors are more sensitive to this decreased function, while most other tissues are less affected.[ citation needed ]

Diagnosis

Typically, a diagnosis of DBA is made through a blood count and a bone marrow biopsy.

A diagnosis of DBA is made on the basis of anemia, low reticulocyte (immature red blood cells) counts, and diminished erythroid precursors in bone marrow. Features that support a diagnosis of DBA include the presence of congenital abnormalities, macrocytosis, elevated fetal hemoglobin, and elevated adenosine deaminase levels in red blood cells. [23]

Most patients are diagnosed in the first two years of life. However, some mildly affected individuals only receive attention after a more severely affected family member is identified.[ citation needed ]About 20–25% of DBA patients may be identified with a genetic test for mutations in the RPS19 gene.

Treatment

Corticosteroids can be used to treat anemia in DBA. In a large study of 225 patients, 82% initially responded to this therapy, although many side effects were noted. [24] Some patients remained responsive to steroids, while efficacy waned in others. Blood transfusions can also be used to treat severe anemia in DBA. Periods of remission may occur, during which transfusions and steroid treatments are not required. Bone marrow transplantation (BMT) can cure hematological aspects of DBA. This option may be considered when patients become transfusion-dependent because frequent transfusions can lead to iron overloading and organ damage. However, adverse events from BMTs may exceed those from iron overloading. [25] A 2007 one-subject study [26] showed the potential efficacy of leucine and isoleucine supplementation.

History

First noted by Hugh W. Josephs in 1936, [1] [27] the condition is however named for the pediatricians Louis K. Diamond and Kenneth Blackfan, who described congenital hypoplastic anemia in 1938. [28] Responsiveness to corticosteroids was reported in 1951. [1] In 1961, Diamond and colleagues presented longitudinal data on 30 patients and noted an association with skeletal abnormalities. [29] In 1997, a region on chromosome 19 was determined to carry a gene mutated in some DBA. [30] [31] In 1999, mutations in the ribosomal protein S19 gene (RPS19) were found to be associated with disease in 42 of 172 DBA patients. [32] In 2001, a second DBA gene was localized to a region of chromosome 8, and further genetic heterogeneity was inferred. [33] Additional genes were subsequently identified. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Myelodysplastic syndrome</span> Diverse collection of blood-related cancers

A myelodysplastic syndrome (MDS) is one of a group of cancers in which immature blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. Early on, no symptoms typically are seen. Later, symptoms may include fatigue, shortness of breath, bleeding disorders, anemia, or frequent infections. Some types may develop into acute myeloid leukemia.

<span class="mw-page-title-main">Fanconi anemia</span> Medical condition

Fanconi anemia (FA) is a rare, autosomal recessive, genetic disease resulting in impaired response to DNA damage in the FA/BRCA pathway. Although it is a very rare disorder, study of this and other bone marrow failure syndromes has improved scientific understanding of the mechanisms of normal bone marrow function and development of cancer. Among those affected, the majority develop cancer, most often acute myelogenous leukemia (AML), MDS, and liver tumors. 90% develop aplastic anemia by age 40. About 60–75% have congenital defects, commonly short stature, abnormalities of the skin, arms, head, eyes, kidneys, and ears, and developmental disabilities. Around 75% have some form of endocrine problem, with varying degrees of severity. 60% of FA is FANC-A, 16q24.3, which has later onset bone marrow failure.

<span class="mw-page-title-main">Chromosome 5q deletion syndrome</span> Human disease

Chromosome 5q deletion syndrome is an acquired, hematological disorder characterized by loss of part of the long arm of human chromosome 5 in bone marrow myelocyte cells. This chromosome abnormality is most commonly associated with the myelodysplastic syndrome.

<span class="mw-page-title-main">Dyskeratosis congenita</span> Medical condition

Dyskeratosis congenita (DKC), also known as Zinsser-Engman-Cole syndrome, is a rare progressive congenital disorder with a highly variable phenotype. The entity was classically defined by the triad of abnormal skin pigmentation, nail dystrophy, and leukoplakia of the oral mucosa, and myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), but these components do not always occur. DKC is characterized by short telomeres. The disease initially can affect the skin, but a major consequence is progressive bone marrow failure which occurs in over 80%, causing early mortality.

<span class="mw-page-title-main">GATA1</span> Protein-coding gene in humans

GATA-binding factor 1 or GATA-1 is the founding member of the GATA family of transcription factors. This protein is widely expressed throughout vertebrate species. In humans and mice, it is encoded by the GATA1 and Gata1 genes, respectively. These genes are located on the X chromosome in both species.

Reticulocytopenia is the medical term for an abnormal decrease in circulating red blood cell precursors (reticulocytes) that can lead to anemia due to resulting low red blood cell (erythrocyte) production. Reticulocytopenia may be an isolated finding or it may not be associated with abnormalities in other hematopoietic cell lineages such as those that produce white blood cells (leukocytes) or platelets (thrombocytes), a decrease in all three of these lineages is referred to as pancytopenia.

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm that features a persistent neutrophilia in peripheral blood, myeloid hyperplasia in bone marrow, hepatosplenomegaly, and the absence of the Philadelphia chromosome or a BCR/ABL fusion gene.

<span class="mw-page-title-main">FANCA</span> Protein-coding gene in the species Homo sapiens

Fanconi anaemia, complementation group A, also known as FAA, FACA and FANCA, is a protein which in humans is encoded by the FANCA gene. It belongs to the Fanconi anaemia complementation group (FANC) family of genes of which 12 complementation groups are currently recognized and is hypothesised to operate as a post-replication repair or a cell cycle checkpoint. FANCA proteins are involved in inter-strand DNA cross-link repair and in the maintenance of normal chromosome stability that regulates the differentiation of haematopoietic stem cells into mature blood cells.

<span class="mw-page-title-main">40S ribosomal protein S19</span> Protein-coding gene in the species Homo sapiens

40S ribosomal protein S19 is a protein that in humans is encoded by the RPS19 gene.

<span class="mw-page-title-main">40S ribosomal protein S10</span> Protein-coding gene in the species Homo sapiens

40S ribosomal protein S10 is a protein that in humans is encoded by the RPS10 gene.

<span class="mw-page-title-main">SBDS</span> Protein-coding gene in the species Homo sapiens

Ribosome maturation protein SBDS is a protein that in humans is encoded by the SBDS gene. An alternative transcript has been described, but its biological nature has not been determined. This gene has a closely linked pseudogene that is distally located. This gene encodes a member of a highly conserved protein family that exists in all archaea and eukaryotes.

<span class="mw-page-title-main">Pyruvate kinase PKLR</span> Protein-coding gene in the species Homo sapiens

Pyruvate kinase PKLR is an enzyme that in humans is encoded by the PKLR gene.

<span class="mw-page-title-main">Acute megakaryoblastic leukemia</span> Blood marrow cancer originating in megakaryoblast cells

Acute megakaryoblastic leukemia (AMKL) is life-threatening leukemia in which malignant megakaryoblasts proliferate abnormally and injure various tissues. Megakaryoblasts are the most immature precursor cells in a platelet-forming lineage; they mature to promegakaryocytes and, ultimately, megakaryocytes which cells shed membrane-enclosed particles, i.e. platelets, into the circulation. Platelets are critical for the normal clotting of blood. While malignant megakaryoblasts usually are the predominant proliferating and tissue-damaging cells, their similarly malignant descendants, promegakaryocytes and megakaryocytes, are variable contributors to the malignancy.

<span class="mw-page-title-main">ALAS2</span> Protein-coding gene in humans

Delta-aminolevulinate synthase 2 also known as ALAS2 is a protein that in humans is encoded by the ALAS2 gene. ALAS2 is an aminolevulinic acid synthase.

Congenital hypoplastic anemia is a congenital disorder that occasionally also includes leukopenia and thrombocytopenia and is characterized by deficiencies of red cell precursors.

<span class="mw-page-title-main">Shwachman–Diamond syndrome</span> Medical condition

Shwachman–Diamond syndrome (SDS), or Shwachman–Bodian–Diamond syndrome, is a rare congenital disorder characterized by exocrine pancreatic insufficiency, bone marrow dysfunction, skeletal and cardiac abnormalities and short stature. After cystic fibrosis (CF), it is the second most common cause of exocrine pancreatic insufficiency in children. It is associated with the SBDS gene and has autosomal recessive inheritance.

Bone marrow failure occurs in individuals who produce an insufficient amount of red blood cells, white blood cells or platelets. Red blood cells transport oxygen to be distributed throughout the body's tissue. White blood cells fight off infections that enter the body. Bone marrow progenitor cells known as megakaryocytes produce platelets, which trigger clotting, and thus help stop the blood flow when a wound occurs.

Ribosomopathies are diseases caused by abnormalities in the structure or function of ribosomal component proteins or rRNA genes, or other genes whose products are involved in ribosome biogenesis.

<span class="mw-page-title-main">Adenosine deaminase 2 deficiency</span> Medical condition

Deficiency of Adenosine deaminase 2 (DADA2) is a monogenic disease associated with systemic inflammation and vasculopathy that affects a wide variety of organs in different patients. As a result, it is hard to characterize a patient with this disorder. Manifestations of the disease include but are not limited to recurrent fever, livedoid rash, various cytopenias, stroke, immunodeficiency, and bone marrow failure. Symptoms often onset during early childhood, but some cases have been discovered as late as 65 years old.

References

  1. 1 2 3 4 Kaushansky, K; Lichtman, M; Beutler, E; Kipps, T; Prchal, J; Seligsohn, U. (2010). "35". Williams Hematology (8th ed.). McGraw-Hill. ISBN   978-0071621519.
  2. ↑ Tchernia, Gilbert; Delauney, J (June 2000). "Diamond–Blackfan anemia" (PDF). Orpha.net. Retrieved 1 January 2010.
  3. ↑ Pelagiadis I, et al. (2023). "The Diverse Genomic Landscape of Diamond–Blackfan Anemia: Two Novel Variants and a Mini-Review". Children. 10 (11): 1812. doi: 10.3390/children10111812 . PMC   10670567 . PMID   38002903.
  4. ↑ Cmejla R, Cmejlova J, Handrkova H, et al. (February 2009). "Identification of mutations in the ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) genes in Czech patients with Diamond–Blackfan anemia". Hum. Mutat. 30 (3): 321–7. doi: 10.1002/humu.20874 . PMID   19191325.
  5. ↑ Reference, Genetics Home. "Diamond-Blackfan anemia". Genetics Home Reference. Retrieved 2018-04-17.
  6. ↑ "Diamond-Blackfan Anemia". Genetic and Rare Diseases Information Center. National Center for Advancing Translational Sciences. February 2023. Retrieved 12 June 2023.
  7. 1 2 Boria, I; Garelli, E; Gazda, H. T.; Aspesi, A; Quarello, P; Pavesi, E; Ferrante, D; Meerpohl, J. J.; Kartal, M; Da Costa, L; Proust, A; Leblanc, T; Simansour, M; Dahl, N; Fröjmark, A. S.; Pospisilova, D; Cmejla, R; Beggs, A. H.; Sheen, M. R.; Landowski, M; Buros, C. M.; Clinton, C. M.; Dobson, L. J.; Vlachos, A; Atsidaftos, E; Lipton, J. M.; Ellis, S. R.; Ramenghi, U; Dianzani, I (2010). "The ribosomal basis of Diamond-Blackfan Anemia: Mutation and database update". Human Mutation. 31 (12): 1269–79. doi:10.1002/humu.21383. PMC   4485435 . PMID   20960466.
  8. 1 2 3 Ulirsch, JC; Verboon, JM; Kazerounian, S; Guo, MH; Yuan, D; Ludwig, LS; Handsaker, RE; Abdulhay, NJ; Fiorini, C; Genovese, G; Lim, ET; Cheng, A; Cummings, BB; Chao, KR; Beggs, AH; Genetti, CA; Sieff, CA; Newburger, PE; Niewiadomska, E; Matysiak, M; Vlachos, A; Lipton, JM; Atsidaftos, E; Glader, B; Narla, A; Gleizes, PE; O'Donohue, MF; Montel-Lehry, N; Amor, DJ; McCarroll, SA; O'Donnell-Luria, AH; Gupta, N; Gabriel, SB; MacArthur, DG; Lander, ES; Lek, M; Da Costa, L; Nathan, DG; Korostelev, AA; Do, R; Sankaran, VG; Gazda, HT (6 December 2018). "The Genetic Landscape of Diamond-Blackfan Anemia". American Journal of Human Genetics. 103 (6): 930–947. doi:10.1016/j.ajhg.2018.10.027. PMC   6288280 . PMID   30503522.
  9. 1 2 3 4 5 Online Mendelian Inheritance in Man. Diamond-Blackfan anemia. Johns Hopkins University.
  10. ↑ Sankaran, Vijay G.; Ghazvinian, Roxanne; Do, Ron; Thiru, Prathapan; Vergilio, Jo-Anne; Beggs, Alan H.; Sieff, Colin A.; Orkin, Stuart H.; Nathan, David G. (2012-07-02). "Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia". Journal of Clinical Investigation. 122 (7): 2439–2443. doi:10.1172/jci63597. PMC   3386831 . PMID   22706301.
  11. ↑ Parrella, Sara; Aspesi, Anna; Quarello, Paola; Garelli, Emanuela; Pavesi, Elisa; Carando, Adriana; Nardi, Margherita; Ellis, Steven R.; Ramenghi, Ugo (2014-07-01). "Loss of GATA-1 full length as a cause of Diamond–Blackfan anemia phenotype". Pediatric Blood & Cancer. 61 (7): 1319–1321. doi:10.1002/pbc.24944. ISSN   1545-5017. PMC   4684094 . PMID   24453067.
  12. ↑ Panici, B; Nakajima, H; Carlston, CM; Ozadam, H; Cenik, C; Cenik, ES (July 2021). "Loss of coordinated expression between ribosomal and mitochondrial genes revealed by comprehensive characterization of a large family with a rare Mendelian disorder". Genomics. 113 (4): 1895–1905. doi:10.1016/j.ygeno.2021.04.020. PMC   8266734 . PMID   33862179. S2CID   233277974.
  13. 1 2 3 4 5 6 7 Hoffbrand, AV; Moss PAH (2011). Essential Haematology (6th ed.). Wiley-Blackwell. ISBN   978-1-4051-9890-5.
  14. ↑ Gazda HT, Grabowska A, Merida-Long LB, et al. (December 2006). "Ribosomal protein S24 gene is mutated in Diamond–Blackfan anemia". Am. J. Hum. Genet. 79 (6): 1110–8. doi:10.1086/510020. PMC   1698708 . PMID   17186470.
  15. ↑ Cmejla R, Cmejlova J, Handrkova H, Petrak J, Pospisilova D (December 2007). "Ribosomal protein S17 gene (RPS17) is mutated in Diamond–Blackfan anemia". Hum. Mutat. 28 (12): 1178–82. doi:10.1002/humu.20608. PMID   17647292. S2CID   22482024.
  16. ↑ Farrar JE, Nater M, Caywood E, et al. (September 2008). "Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond–Blackfan anemia". Blood. 112 (5): 1582–92. doi:10.1182/blood-2008-02-140012. PMC   2518874 . PMID   18535205.
  17. 1 2 3 Gazda H. T.; Sheen M. R.; Vlachos A.; et al. (2008). "Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients". The American Journal of Human Genetics. 83 (6): 769–80. doi:10.1016/j.ajhg.2008.11.004. PMC   2668101 . PMID   19061985.
  18. ↑ Online Mendelian Inheritance in Man (OMIM): 603632
  19. 1 2 Online Mendelian Inheritance in Man (OMIM): 603701
  20. ↑ Online Mendelian Inheritance in Man (OMIM): 604174
  21. 1 2 3 Gripp K W; Curry C; Olney A H; Sandoval C; Fisher J; Chong J X; UW Center for Mendelian Genomics; Pilchman L; Sahraoui R; Stabley D L; Sol-Church K (2014). "Diamond-Blackfan anemia with mandibulofacial dystostosis is heterogeneous, including the novel DBA genes TSR2 and RPS28". American Journal of Medical Genetics. 164A (9): 2240–9. doi:10.1002/ajmg.a.36633. PMC   4149220 . PMID   24942156.
  22. ↑ Gazda H, Lipton JM, Willig TN, et al. (April 2001). "Evidence for linkage of familial Diamond–Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease". Blood. 97 (7): 2145–50. doi: 10.1182/blood.V97.7.2145 . PMID   11264183.
  23. ↑ Williamson, MA; Snyder, LM. (2015). "Chapter 9". Wallach's Interpretation of Diagnostic Tests (10th ed.). Lippincott Williams & Wilkins. ISBN   9781451191769.
  24. ↑ Vlachos A, Klein GW, Lipton JM (2001). "The Diamond Blackfan Anemia Registry: tool for investigating the epidemiology and biology of Diamond–Blackfan anemia". J. Pediatr. Hematol. Oncol. 23 (6): 377–82. doi:10.1097/00043426-200108000-00015. PMID   11563775.
  25. ↑ Saunders, E. F.; Olivieri, N; Freedman, M. H. (1993). "Unexpected complications after bone marrow transplantation in transfusion-dependent children". Bone Marrow Transplantation. 12 (Suppl 1): 88–90. PMID   8374573.
  26. ↑ Pospisilova D, Cmejlova J, Hak J, Adam T, Cmejla R (2007). "Successful treatment of a Diamond–Blackfan anemia patient with amino acid leucine". Haematologica. 92 (5): e66–7. doi: 10.3324/haematol.11498 . PMID   17562599.
  27. ↑ Hugh W. Josephs (1936). "Anaemia of infancy and early childhood". Medicine (Baltimore). 15 (3): 307–451. doi: 10.1097/00005792-193615030-00001 .
  28. ↑ Diamond LK, Blackfan KD (1938). "Hypoplastic anemia". Am. J. Dis. Child. 56: 464–467.
  29. ↑ Diamond LK, Allen DW, Magill FB (1961). "Congenital (erythroid) hypoplastic anemia: a 25 year study". Am. J. Dis. Child. 102 (3): 403–415. doi:10.1001/archpedi.1961.02080010405019. PMID   13722603.
  30. ↑ Gustavsson P, Willing TN, van Haeringen A, Tchernia G, Dianzani I, Donner M, Elinder G, Henter JI, Nilsson PG, Gordon L, Skeppner G, van't Veer-Korthof L, Kreuger A, Dahl N (1997). "Diamond–Blackfan anaemia: genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb". Nat. Genet. 16 (4): 368–71. doi:10.1038/ng0897-368. PMID   9241274. S2CID   6972423.
  31. ↑ Gustavsson P, Skeppner G, Johansson B, Berg T, Gordon L, Kreuger A, Dahl N (1997). "Diamond–Blackfan anaemia in a girl with a de novo balanced reciprocal X;19 translocation". J. Med. Genet. 34 (9): 779–82. doi:10.1136/jmg.34.9.779. PMC   1051068 . PMID   9321770.
  32. ↑ Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, Ball S, Tchernia G, Klar J, Matsson H, Tentler D, Mohandas N, Carlsson B, Dahl N (1999). "The gene encoding ribosomal protein S19 is mutated in Diamond–Blackfan anaemia". Nat. Genet. 21 (2): 168–75. doi:10.1038/5951. PMID   9988267. S2CID   26664929.
  33. ↑ Gazda H, Lipton JM, Willig TN, Ball S, Niemeyer CM, Tchernia G, Mohandas N, Daly MJ, Ploszynska A, Orfali KA, Vlachos A, Glader BE, Rokicka-Milewska R, Ohara A, Baker D, Pospisilova D, Webber A, Viskochil DH, Nathan DG, Beggs AH, Sieff CA (2001). "Evidence for linkage of familial Diamond–Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease". Blood. 97 (7): 2145–50. doi: 10.1182/blood.V97.7.2145 . PMID   11264183.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.